

BEST OF ASCO UAE 2023



24 – 25 JUNE, 2023



GRAND HYATT, ABU DHABI, UAE

DAY 1

AGENDA



24TH JUNE, 2023
SATURDAY



09:00 – 17:00 HRS
UAE TIME

09:00 - 09:10

Introduction

Dr. Jawaher Ansari, UAE - Chairman of the Conference

Dr. Khalid Balaraj, UAE - Co-chairman of the Conference

SESSION 1 - PLENARY SESSION

Chairperson: Dr. Jawaher Ansari, UAE | Dr. Diaeddine Trad, UAE

09:10 – 09:20

PROSPECT: A Randomized Phase III Trial of Neoadjuvant Chemoradiation Versus Neoadjuvant FOLFOX Chemotherapy with Selective Use of Chemoradiation, Followed by Total Mesorectal Excision (TME) for Treatment of Locally Advanced Rectal Cancer (LARC) (Alliance N1048)

Prof. Daniel Palmer, UK

09:20 – 09:30

OS Survival Analysis from the ADURA Trial of Adjuvant Osimertinib in Patients with Resected EGFR-mut Stage 1B-IIIa NSCLC

Dr. Emad Dawoud, UAE

09:30 – 09:40

INDIGO: A Global, Randomized, Double-blinded, Phase 3 Study of Vorasidenib versus Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation

Dr. Selvaraj Giridharan, UAE

09:40 – 09:50

Phase 3 THOR Study: Results of Erdafitinib (erda) versus Chemotherapy (chemo) in Patients (pts) with Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Receptor Alterations (FGFRalt). (LBA4619)

Prof. Syed Hussain, UK

09:50 – 10:20

Panel Discussion and Q&A's

Moderator: **Dr. Jawaher Ansari, UAE**

Panelists: **Dr. Diaeddine Trad, UAE | Prof. Daniel Palmer, UK |
Dr. Emad Dawoud, UAE | Dr. Selvaraj Giridharan, UAE |
Prof. Syed Hussain, UK | Dr Mohammed Asha, UAE**

10:20 - 11:00

OPENING CEREMONY

11:00 - 11:20

Coffee Break

SESSION 2 - EARLY BREAST CANCER

Chairperson: Dr. Aydah Al Awadhi, UAE | Dr. Aly Abdel Razek, UAE | Dr. Faisal Al Terkait, Kuwait

- 11:20 – 11:30 Ribociclib and Endocrin Therapy as Adjuvant Treatment in Patients with HR+/HER2– Early Breast Cancer: Primary Results of the Phase III NATALEE Trial
Prof. Michael Gnant, Austria
- 11:30 – 11:40 Efficacy and Safety Results by Age in Monarche: Adjuvant Abemaciclib Combined with Endocrine Therapy (ET) in Patients with HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer (EBC)
Dr. Farooq Latif, UAE
- 11:40 – 11:50 Effects of Ovarian Ablation or Suppression on Breast Cancer Recurrence and Survival: Patient-Level Meta-Analysis of 14,993 Pre-Menopausal Women in 25 Randomized Trials
Dr. Anwar AlNouri, Kuwait
- 11:50 – 12:00 Nine-Weeks versus One-Year Trastuzumab for Early-Stage HER2+ Breast Cancer: 10-year Update of the Short-HER Phase III Randomized Trial
Dr. Saeed Rafii, UAE
- 12:00 – 12:15 Optimizing CDK4&6i Outcome for HR+, HER2- High Risk EBC Patients
Satellite Symposium by Lilly
Moderator: **Dr. Aydah Al Awadhi, UAE**
Speaker: **Dr. Olga Oikonomidou, UK**
- 12:15 – 12:30 Perspectives in HR+/HER2– Early Breast Cancer
Satellite Symposium by Novartis
Moderator: **Dr. Faisal Al Terkait, Kuwait**
Speaker: **Prof. Michael Gnant, Austria**
- 12:30 – 13:00 Panel Discussion and Q&A's
Moderator: **Dr. Aydah Al Awadhi, UAE**
Panelists: **Dr. Farooq Latif, UAE | Dr. Anwar AlNouri, Kuwait | Prof. Michael Gnant, Austria | Dr. Olga Oikonomidou, UK | Dr. Faisal Terkait, Kuwait | Dr. Aly Abdel Razek, UAE | Dr. Saeed Rafii, UAE**

13:00 - 14:00 Lunch Break

SESSION 3 - ADVANCED BREAST CANCER

Chairperson: Dr. Nouri Bennini, UAE | Dr. Hassan Ghazal, UAE | Dr. Abdulwahhab Altourah, Kuwait

- 14:00 – 14:10 Final Overall Survival (OS) Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) with Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)
Dr. Faraz Khan, UAE
- 14:10 – 14:20 Primary Outcome Analysis of the Phase 3 SONIA Trial (BOOG 2017-03) on Selecting the Optimal Position of Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitors for Patients with Hormone Receptor-Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (ABC)
Dr. Husam Marashi, UAE
- 14:20 – 14:30 A Phase 2 study of HER3-DXd in Patients (pts) with Metastatic Breast Cancer (MBC)
Dr. Dorai Ramanathan, UAE




- 14:30 – 14:45 Evolving Paradigm in Management of Metastatic HER2+ Breast Cancer - *Satellite Symposium by MSD*
Dr. Aydah Al Awadhi, UAE
- 14:45 – 15:00 HR+/HER2- Advanced Breast Cancer: How the Latest Data Inform Treatment Decision?
Satellite Symposium by Novartis
Moderator: Dr. Anwar Al Nouri, Kuwait
Speaker: Dr. Emad Dawoud, UAE
- 15:00 – 15:15 **Panel Discussion and Q&A's**
Moderator: Dr. Nouri Bennini, UAE
**Panelists: Dr. Faraz Khan, UAE | Dr. Husam Marashi, UAE |
Dr. Dorai Ramanathan, UAE | Dr. Aydah Al Awadhi, UAE |
Dr. Hassan Ghazal, UAE | Dr. Emad Dawoud, UAE**
- 15:15 - 15:30 Coffee break

SESSION 4 - LUNG CANCER

Chairperson: Dr. Ramanujam Singarachari, UAE | Dr. Hassan Jaafar, UAE | Dr. Selvaraj Giridharan, UAE

- 15:30 – 15:40 KEYNOTE-671: Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo Plus Platinum-Based Chemotherapy Followed by Resection and Pembrolizumab or Placebo for Early-Stage NSCLC
Dr. Fathi Azribi, UAE
- 15:40 – 15:50 IND227 Phase III (P3) Study of Cisplatin/Pemetrexed (CP) with or without Pembrolizumab (Pembro) in Patients (pts) with Malignant Pleural Mesothelioma (PM): A CCTG, NCIN, and IFCT Trial
Dr. Aref Chehal, UAE
- 15:50 – 16:00 Pemetrexed and Platinum with or without Pembrolizumab for Tyrosine Kinase Inhibitor (TKI)-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC: Phase 3 KEYNOTE-789 Study
Dr. Emad Dawoud, UAE
- 16:00 – 16:10 Perioperative Toripalimab + Platinum-Doublet Chemotherapy vs Chemotherapy in Resectable Stage II/III Non-Small Cell Lung
Dr. Cherian Thampy, UAE
- 16:10 – 16:25 Long Term Clinical Outcome of DUAL IO in 1L NSCLC - *Satellite Symposium by BMS*
Dr. Selvaraj Giridharan, UAE
- 16:25 – 16:40 Cancer Immunotherapy Advances in Early Lung Cancer - *Satellite Symposium by Roche*
Moderator: Dr. Dina Hamza, UAE
Speaker: Dr. Emad Dawoud, UAE
- 16:40 – 17:00 **Panel Discussion and Q&A's**
Moderator: Dr. Emad Dawoud, UAE
**Panelists: Dr. Hassan Jaafar, UAE | Dr. Cherian Thampy, UAE | Dr. Fathi Azribi, UAE |
Dr. Aref Chehal, UAE | Dr. Ramanujam Singarachari, UAE |
Dr. Selvaraj Giridharan, UAE**

17:00 Closing Remarks



BEST OF ASCO UAE 2023



24 – 25 JUNE, 2023



GRAND HYATT, ABU DHABI, UAE

DAY 2

AGENDA



25TH JUNE, 2023
SUNDAY



09:00 – 15:30 HRS
UAE TIME

09:00

Introduction
Dr. Diaeddine Trad, UAE

SESSION 5 - GASTROINTESTINAL CANCERS

Chairperson: Dr. Diaeddine Trad, UAE | Dr. Husam Marashi, UAE | Dr. Bassim Bahrani, Oman

- 09:00 – 09:10 Efficacy, Safety and Patient Reported Outcomes (PROs) from the Phase III IMbrave050 Trial of Adjuvant Atezolizumab (atezo) + Bevacizumab (bev) vs Active Surveillance in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Disease Recurrence Following Resection or Ablation
Prof. Daniel Palmer, UK
- 09:10 – 09:20 Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) versus Nab-Paclitaxel + Gemcitabine in Treatment-Naive Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac): 12- And 18-Month Survival Rates from the Phase 3 NAPOLI 3 Trial
Dr. Muhammad Nasim, UAE
- 09:20 – 09:30 Phase III Randomized Clinical Trial Comparing the Efficacy of Neoadjuvant Chemotherapy and Standard Treatment in Patients with Locally Advanced colon Cancer: The NeoCol Trial
Dr. Dina Hamza, UAE
- 09:30 – 09:40 Phase III FIRE-4 study (AIO KRK-0114): Influence of Baseline Liquid Biopsy Results in First-Line Treatment Efficacy of FOLFIRI/Cetuximab in Patients with Tissue RAS-WT mCRC
Dr. Maroun Khoury, UAE
- 09:40 – 09:55 The Evolving Role of Immuno-Oncology Combination for the Management of 1L Gastric Cancer
Satellite Symposium by BMS
Dr. Emad Dawoud, UAE
- 09:55 – 10:10 Advancement in the Management of Advanced or Unresectable HCC: The Era of IO-IO Combination
Satellite Symposium by AstraZeneca
Dr. Selvaraj Giridharan, UAE
- 10:10 – 10:25 Efficacy of Ramucirumab Paclitaxel Combination After IOs in 1st Line Advanced Gastric Cancer
Satellite Symposium by Lilly
Dr. Nouri Bennini, UAE



10:25 – 10:40

Panel Discussion and Q&A's

Moderator: **Dr. Diaeddine Trad, UAE**

Panelists: **Dr. Dina Hamza, UAE | Dr. Maroun Khoury, UAE | Dr. Muhammad Nasim, UAE | Prof. Daniel Palmer, UK | Dr. Bassim Bahrani, Oman**

10:40 - 11:00

Coffee Break

SESSION 6 - GENITOURINARY CANCERS

Chairperson: **Dr. Faisal Azam, KSA | Dr. Ehab Abdou, KSA | Dr. Nouri Bennini, UAE**

11:00 - 11:10

Prostate Irradiation in Men with De Novo, Low-Volume, Metastatic, Castration-Sensitive Prostate Cancer (MCSPC): Results of PEACE-1, a Phase 3 Randomized Trial with a 2x2 Design

Dr. Rana Mahmood, UAE

11:10 – 11:20

TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) versus Placebo (PBO) + ENZA as First-Line (1L) Treatment for Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Harboring Homologous Recombination Repair (HRR) Gene Alterations

Dr. Bassam Basulaiman, KSA

11:20 – 11:30

Efficacy and Safety of Atezolizumab plus Cabozantinib Vs Cabozantinib alone after Progression with Prior Immune Checkpoint Inhibitor (ICI) Treatment in Metastatic Renal Cell Carcinoma (RCC): Primary PFS Analysis from the Phase 3, Randomized, Open-Label CONTACT-03 Study

Dr. Hassan Shahryar, UAE

11:30 – 11:40

Final Prespecified Overall Survival (OS) Analysis of CLEAR: 4-year Follow-up of Lenvatinib plus Pembrolizumab (L+P) vs Sunitinib (S) in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC)

Dr. Jawaher Ansari, UAE

11:40 – 11:50

Study EV-103 Dose Escalation/cohort A: Long-term Outcome of Enfortumab vedotin + Pembrolizumab in First-Line (1L) Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with Nearly 4 Years of Follow-up

Prof. Syed Hussain, UK

11:50 – 12:05

Innovation Unveiled: Enfortumab Vedotin "PADCEV" Impact on Urothelial Cancer

Satellite Symposium by Astellas

Moderator: **Dr. Nouri Bennini, UAE**

Speaker: **Dr. Jawaher Ansari, UAE**

12:05 – 12:30

Panel Discussion and Q&A's

Moderator: **Dr. Faisal Azam, KSA**

Panelists: **Dr. Ehab Abdou, KSA | Prof. Syed Hussain, UK | Dr. Rana Mahmood, UAE | Dr. Bassam Basulaiman, KSA | Dr. Jawaher Ansari, UAE | Dr. Hassan Shahryar, UAE | Dr. Nouri Bennini, UAE**

12:30 - 14:00

Lunch Break



SESSION 7- PRACTICE CHANGING DATA

Chairperson: Dr. Ashish Chintakuntlawar, UAE | Dr. Hassan Ghazal, UAE | Dr. Muhammad Nasim, UAE |
Dr. Abdul Rahman Kinge, UAE

- 14:00 – 14:20 Summary of Practice-Changing Data Lecture Breast
Dr. Sharif Kullab, KSA
- 14:20 – 14:40 Summary of Practice-Changing Data Lecture GI
Dr. Husam Marashi, UAE
- 14:40 – 15:00 Summary of Practice-Changing Data Lecture GU
Dr. Faisal Azam, KSA
- 15:00 – 15:20 Summary of Practice-Changing Data Lecture Lung
Dr. Selvaraj Giridharan, UAE
- 15:20 – 15:30 **Panel Discussion and Q&As**
Moderator: Dr. Hassan Ghazal, UAE
Panelists: Dr. Ashish Chintakuntlawar, UAE | Dr. Sharif Kullab, KSA |
Dr. Abdul Rahman Kinge, UAE | Dr. Faisal Azam, KSA |
Dr. Selvaraj Giridharan, UAE | Dr. Muhammad Nasim, UAE |
Dr. Husam Marashi, UAE
- 15:30 Closing Remarks

